Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP/DDIT3↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
3157- Ash,    Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
- in-vivo, Ovarian, A2780S
*cachexia↑, *UPR↑, Strength↑,
3158- Ash,    Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I
- Study, NA, NA
Prx↓,
3159- Ash,    Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model
- in-vitro, Park, SH-SY5Y
*neuroP↑, *Inflam↓, *ROS↓, *cognitive↑, *memory↑, *GPx↑, *Prx↓, *ATP↑, *Vim↓, *mtDam↓,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP/DDIT3↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
3161- Ash,    Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage
- in-vivo, Stroke, NA
*neuroP↑, *MDA↓, *ROS↓, *SOD↑, *GPx↑, *NRF2↑, *HO-1↑,
3163- Ash,  Rad,    Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis
*radioP↑, selectivity↑, *Casp3↓, *DNAdam↓, *ROS↓, *GSH↓, *NRF2↑, *HO-1↑, *Catalase↑, *SOD↑, *Prx↑, *ERK↑,
3164- Ash,    Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3
*hepatoP↑, *IKKα↓, *NLRP3↓, *NRF2↑, *AMPK↑, *Inflam↓, *Apoptosis↓, *cl‑Casp3↓, *cl‑PARP1↓, *NLRP3↓, *ROS↓, *ALAT↓, *AST↓, *GSH↑,
3165- Ash,    Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells
- in-vitro, Nor, NA
*IL8↓, *Inflam↓,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
3167- Ash,    Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
- in-vitro, MM, H226
TumCP↓, cMyc↓, cFos↓, cJun↓, TIMP2↑, Vim↓, ROS↑, BAX↑, IKKα↑, Casp3↑, cl‑PARP↑,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
lipid-P↓, SOD↑, GPx↑, P53↑, Bcl-2↑, E6↓, E7↓, pRB↑, CycB/CCNB1↑, CDC2↑, P21↑, PCNA↓, ALDH1A1↓, Vim↓, Glycolysis↓, cMyc↓, BAX↑, NF-kB↓, Casp3↑, CHOP/DDIT3↑, DR5↑, ERK↓, Wnt↓, β-catenin/ZEB1↓, Akt↓, HSP90↓,
5384- AsP,  MEL,    Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy
- in-vivo, Var, NA
AntiCan↑, TumCG↓, Apoptosis↑, DNAdam↑, TumCCA↑, IL6↓, STAT3↓, TumCP↓, Ki-67↓, TumCI↓, TumMeta↓, MMP9↓, eff↑, *Catalase↑, *SOD↑, *GSH↑, *MDA↓, *NO↓, *antiOx↑, *hepatoP↑, *RenoP↑,
5385- AsP,  GoldNP,  GEM,    Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery
- in-vitro, BC, NA
ROS↑, Fenton↑, BioAv↑, EPR↑,
5388- AsP,    Capacity of Ascorbyl Palmitate to Produce the Ascorbyl Radical in Vitro: an Electron Spin Resonance Investigation
- in-vitro, Nor, NA
other↑,
5389- AsP,  Tras,    ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
tumCV↓, eff↑, P53↑, BAX↑, Casp3↑, Casp8↑, Bcl-2↓, Apoptosis↑, p‑p38↓, ERK↓, PI3K↓,
5391- AsP,    Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy
- Review, Var, NA
*antiOx↑, toxicity↓,
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
1146- AsP,    Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms
- in-vivo, Nor, NA
TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,
5426- ASTX,  Cisplatin,    Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)
- Trial, HNSCC, NA
ROS↓, SOD↑, MDA↓, eff↑,
5427- ASTX,    Astaxanthin and Cancer Chemoprevention
- Review, Var, NA
chemoP↑, AntiCan↑, chemoPv↑, Risk↓, lipid-P↓, Pain↓, BioAv↑, Dose↝,
5417- ASTX,    Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers
- Study, Nor, NA
*antiOx↑, *BioAv↓, *Dose↝, *BioAv↑,
5418- ASTX,    Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials
- Review, Nor, NA
*MDA↓, *SOD↑, *IL6↓, *ROS↓, *Inflam↓,
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,
5420- ASTX,    A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies
- in-vivo, Nor, NA
*eff↑, *SOD↑, *BioAv↑,
5421- ASTX,    Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice
- in-vivo, Pca, NA
TumCG↑, Ki-67↑, PCNA↓, GutMicro↑, *Inflam↓, *cardioP↑, *ROS↓,
5422- ASTX,    Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats
- in-vivo, Nor, NA
*antiOx↑, *AntiDiabetic↑, *toxicity∅, *BioAv↓, *BioAv↑,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5424- ASTX,    Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity
- in-vivo, Nor, NA
*GutMicro↑, AntiCan↑, eff↑, AntiTum↑, ChemoSen↑,
5425- ASTX,    Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
- in-vivo, AD, NA
*neuroP↑, *antiOx↑, *Inflam↑, *AChE↓, *BACE↓, *MAOA↓, *Aβ↓, *memory↑, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑, *NF-kB↓, *GSK‐3β↓, *ChAT↑, *iNOS↓, *ROS↓, *BBB↑,
4814- ASTX,    Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review
- Review, Var, NA
Apoptosis↑, EMT↓, AntiCan↑, *cardioP↑, *neuroP↑, TumCG↓, *antiOx↑, *Bacteria↓, *Imm↑, *hepatoP↑, *AntiDiabetic↑, ROS↓, *chemoPv↑,
4825- ASTX,    In vivo protective efficacy of astaxanthin against ionizing radiation-induced DNA damage
- in-vivo, Nor, NA
*DNAdam↓, *radioP↑,
4824- ASTX,  Rad,    Astaxanthin protects the radiation-induced lung injury in C57BL/6 female mice
- in-vivo, Nor, NA
*radioP↑, Inflam↓,
4823- ASTX,    Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest
- in-vitro, ESCC, NA
RadioS↑, Apoptosis↑, TumCCA↑, Bcl-2↓, CycB/CCNB1↓, CDC2↓, BAX↑,
4822- ASTX,  Rad,    Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC)
tumCV↓, selectivity↑, RadioS↑, GPx4↓, Ferroptosis↑,
4821- ASTX,    Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
- in-vitro, BC, SkBr3 - in-vitro, BC, BT20 - in-vitro, BC, T47D
Apoptosis↑, CSCs↓, OCT4↓, Nanog↓, TumCP↓,
4820- ASTX,    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p
- in-vitro, NPC, NA
TumCP↓, TumCI↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, Bcl-2↓, P21↑, BAX↑, PI3K↓, Akt↓, NF-kB↓, miR-29b↑,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4818- ASTX,  MEL,    Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
TumCD↑, DNAdam↑, *antiOx↑, *AntiTum↑, Inflam↓, tumCV↓, Bcl-2↓, Apoptosis↓, selectivity↑, eff↑, Dose↓,
4817- ASTX,    Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53
- in-vitro, GBM, U251
Dose⇅, ROS∅, SOD↑, CDK1↑, P53↓, TumCP⇅, ROS↑,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
4813- ASTX,    Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function
- in-vitro, AD, NA
*antiOx↑, *Apoptosis↓, *AntiTum↑, *ROS↓, *MMP↑, *neuroP↑,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4809- ASTX,    Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression
- in-vitro, GC, AGS - in-vitro, GC, MKN45
tumCV↓, TumCP↓, TumCCA↑, p‑ERK↓, p27↑, cycD1/CCND1↓, CDK4↓,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,

Showing Research Papers: 1001 to 1050 of 7368
Prev Page 21 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7368

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   ATF3↑, 1,   Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 2,   GSH↓, 1,   GSR↑, 1,   HO-1↑, 3,   Iron↑, 1,   lipid-P↓, 2,   lipid-P↑, 1,   MDA↓, 2,   NQO1↑, 2,   NRF2↑, 3,   OXPHOS↓, 1,   Prx↓, 1,   ROS↓, 4,   ROS↑, 6,   ROS⇅, 1,   ROS∅, 1,   SIRT3↑, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 2,   CDC2↑, 1,   mitResp↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   AMPK↑, 1,   cMyc↓, 3,   FASN↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 1,   NADPH↑, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 6,   Akt↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 16,   BAX↑, 6,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 7,   Bcl-2↑, 1,   BIM↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 2,   Casp8↑, 1,   cl‑Casp9↑, 1,   Chk2↓, 1,   Cyt‑c↑, 1,   DR5↑, 2,   Ferroptosis↑, 2,   HEY1↓, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 1,   p27↑, 1,   p38↑, 2,   p‑p38↓, 1,   TumCD↑, 4,  

Kinase & Signal Transduction(tgid=6) ⓘ

RET↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   H3↑, 1,   other↑, 2,   pRB↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   eIF2α↓, 1,   ER Stress↑, 1,   HSP90↓, 4,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   DNAdam↑, 2,   P53↓, 1,   P53↑, 4,   PARP↑, 1,   cl‑PARP↑, 1,   PARP1↑, 1,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1↑, 1,   CDK2↓, 1,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 4,   p‑RB1↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD44↓, 1,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 4,   EMT↓, 5,   ERK↓, 3,   p‑ERK↓, 1,   FOXO3↑, 2,   GSK‐3β↑, 1,   mTOR↓, 1,   Nanog↓, 2,   NOTCH↓, 1,   NOTCH1↓, 1,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 5,   PI3K↑, 1,   SOX2↓, 1,   STAT3↓, 6,   TumCG↓, 4,   TumCG↑, 1,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

AP-1↓, 2,   E-cadherin↑, 1,   ER-α36↓, 1,   Ki-67↓, 1,   Ki-67↑, 1,   miR-200b↑, 1,   miR-29b↑, 2,   MMP1↓, 1,   MMP2↓, 3,   MMP9↓, 4,   MMPs↓, 3,   N-cadherin↓, 3,   Slug↓, 1,   Snail↓, 1,   TIMP2↑, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 10,   TumCP↑, 1,   TumCP⇅, 1,   TumMeta↓, 4,   uPA↓, 2,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↑, 1,   EPR↑, 2,   NO↓, 1,   PDGFR-BB↓, 1,   VEGF↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IKKα↑, 1,   IL6↓, 3,   Inflam↓, 2,   NF-kB↓, 5,   PSA↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 5,   BioAv↝, 1,   ChemoSen↑, 4,   ChemoSen⇅, 1,   Dose↓, 1,   Dose↑, 1,   Dose⇅, 1,   Dose↝, 3,   eff↑, 11,   RadioS↑, 3,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

E6↓, 3,   E7↓, 3,   GutMicro↑, 1,   IL6↓, 3,   Ki-67↓, 1,   Ki-67↑, 1,   LDH↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 7,   AntiTum↑, 3,   chemoP↑, 3,   chemoPv↑, 1,   neuroP↑, 1,   Pain↓, 1,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 188

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 15,   Catalase↑, 2,   GPx↑, 2,   GSH↓, 1,   GSH↑, 3,   HO-1↑, 3,   lipid-P↓, 1,   MDA↓, 4,   NRF2↑, 6,   Prx↓, 1,   Prx↑, 2,   ROS↓, 9,   SOD↑, 7,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   MMP↑, 1,   mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 2,   p‑PPARγ↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   Casp3?, 1,   Casp3↓, 1,   cl‑Casp3↓, 1,   iNOS↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

UPR↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 2,   cl‑PARP1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   ERK↑, 1,   GSK‐3β↓, 1,  

Migration(tgid=13) ⓘ

Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↓, 2,   IKKα↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 3,   IL8↓, 3,   Imm↑, 1,   Inflam↓, 8,   Inflam↑, 1,   NF-kB↓, 3,   PGE2↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,   NLRP3↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 6,   BioAv↝, 3,   Dose↑, 1,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   GutMicro↑, 1,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↓, 1,   AntiDiabetic↑, 2,   AntiTum↑, 2,   cachexia↑, 1,   cardioP↑, 4,   chemoPv↑, 2,   cognitive↑, 1,   hepatoP↑, 4,   memory↑, 2,   neuroP↑, 7,   radioP↑, 3,   RenoP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 79

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page